Aizawa Peter, Winge Stefan, Karlsson Göran
Octapharma AB, SE-11275 Stockholm, Sweden.
Thromb Res. 2008;122(4):560-7. doi: 10.1016/j.thromres.2007.12.027. Epub 2008 Mar 10.
Thrombin was prepared from human blood plasma (batch size 1200 L). First, prothrombin was isolated by the following separation techniques: cryoprecipitation, ion-exchange chromatography (diethyl aminoethyl, DEAE-IEX), heparin affinity chromatography, a second DEAE-IEX step, and immobilized metal-affinity chromatography (IMAC). Prothrombin was then activated to thrombin, which was purified by hydrophobic interaction chromatography (HIC) and concentrated by ultrafiltration. This process is cost-effective because a waste fraction can be used from one of the steps (heparin affinity chromatography) in the commercial production of plasma-derived Factor IX (FIX). The final thrombin preparation had a purity of approximately 75% (specific activity approximately 2400 IU/mg protein), which is sufficient for its intended purpose in a fibrin glue. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Factor X (FX) activity analysis, and analytical HIC were also used to characterize the thrombin. Three substantially different techniques were used to reduce any viral activity, namely: solvent/detergent (S/D) treatment, pasteurization, and virus filtration (nanofiltration). The manufacturing process presented here would be suitable for large-scale production of thrombin with a high degree of virus safety.
凝血酶由人血浆制备(批量为1200升)。首先,通过以下分离技术分离凝血酶原:冷沉淀、离子交换色谱法(二乙氨基乙基,DEAE - IEX)、肝素亲和色谱法、第二步DEAE - IEX以及固定化金属亲和色谱法(IMAC)。然后将凝血酶原激活为凝血酶,凝血酶通过疏水相互作用色谱法(HIC)纯化并通过超滤浓缩。该过程具有成本效益,因为在血浆源性因子IX(FIX)的商业生产中,其中一个步骤(肝素亲和色谱法)产生的废馏分可被利用。最终的凝血酶制剂纯度约为75%(比活性约为2400 IU/mg蛋白质),足以满足其在纤维蛋白胶中的预期用途。还使用十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS - PAGE)、因子X(FX)活性分析和分析型HIC对凝血酶进行表征。使用了三种截然不同的技术来降低任何病毒活性,即:溶剂/去污剂(S/D)处理、巴氏消毒和病毒过滤(纳滤)。此处介绍的生产工艺适用于大规模生产具有高度病毒安全性的凝血酶。